Dolby Stock Down 18%, Yet This $8 Million Bet Signals Turnaround Potential

DLB -0.83% F +1.95% ^GSPC +0.05% ROIV -1.12% NVDA -2.21%

On February 13, 2026, Neo Ivy Capital Management disclosed a new position in Dolby Laboratories (NYSE:DLB), acquiring 117,964 shares in a trade estimated at $7.58 million.

What happened

Neo Ivy Capital Management reported in a February 13, 2026, SEC filing that it established a new stake in Dolby Laboratories, acquiring 117,964 shares. The estimated transaction value was $7.58 million.

What else to know

• This new position in DLB represents 1.2% of Neo Ivy’s reportable U.S. equity AUM after the fourth quarter filing.

• Top holdings after the filing:

  • NYSE: F: $7.61 million (1.2% of AUM)

  • NYSE: DLB: $7.58 million (1.2% of AUM)

  • NYSE: WELL: $7.56 million (1.2% of AUM)

  • NASDAQ: ROIV: $7.41 million (1.2% of AUM)

  • NASDAQ: NVDA: $7.35 million (1.2% of AUM)

• As of February 12, 2026, shares of DLB were priced at $66.57, down 18.2% over the past year and underperforming the S&P 500 by 31.08 percentage points.

Company overview

Metric

Value

Price (as of market close 2026-02-12)

$66.57

Market Capitalization

$6.37 billion

Revenue (TTM)

$1.34 billion

Net Income (TTM)

$276.72 million

Company snapshot

• Dolby Laboratories develops and licenses advanced audio and imaging technologies, including Dolby Atmos, Dolby Vision, and a suite of digital codecs for cinema, broadcast, streaming, and consumer electronics.

• The company generates revenue primarily through technology licensing agreements and sales of specialized hardware for entertainment and communications markets.

• It serves film studios, content creators, post-production facilities, cinema operators, broadcasters, and device manufacturers worldwide.

Dolby Laboratories is a leading provider of audio and imaging innovations, leveraging its proprietary technologies to enhance entertainment experiences across multiple platforms. The company combines a robust licensing model with hardware solutions, enabling global reach and recurring revenue streams. Its established presence in both professional and consumer markets supports sustained growth and a defensible competitive position.

What this transaction means for investors

Durable licensing franchises rarely trade at discounts for long. That tension makes this new stake in Dolby worth watching.Shares are down 18.2% over the past year, but the fundamentals tell a steadier story. In the first quarter of fiscal 2026, revenue totaled $347 million, down from $357 million one year prior but with $319.8 million coming from high-margin licensing streams. Meanwhile, gross profit reached $303.5 million, and the company generated $53.3 million in GAAP net income. And even more telling, Dolby repurchased roughly 1 million shares for about $70 million and still ended the quarter with $207 million remaining under its buyback authorization.That matters because this is not a capital-intensive turnaround story. It is a licensing machine with roughly 90% gross margins and a balance sheet showing over $640 million in cash and equivalents. Compared with other holdings clustered around cyclical industrial and commodity names, this adds a royalty-driven, asset-light counterweight.

Should you buy stock in Dolby Laboratories right now?

Before you buy stock in Dolby Laboratories, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Dolby Laboratories wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $409,108!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,145,980!*

Now, it’s worth noting Stock Advisor’s total average return is 886% — a market-crushing outperformance compared to 193% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of February 13, 2026.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Dolby Laboratories, Nvidia, and Palantir Technologies. The Motley Fool recommends Roivant Sciences. The Motley Fool has a disclosure policy.

Dolby Stock Down 18%, Yet This $8 Million Bet Signals Turnaround Potential was originally published by The Motley Fool